Literature DB >> 25670809

Towards an HBV cure: state-of-the-art and unresolved questions--report of the ANRS workshop on HBV cure.

Mirjam B Zeisel1, Julie Lucifora2, William S Mason3, Camille Sureau4, Jürgen Beck5, Massimo Levrero6, Michael Kann7, Percy A Knolle8, Monsef Benkirane9, David Durantel2, Marie-Louise Michel10, Brigitte Autran11, François-Loïc Cosset12, Hélène Strick-Marchand13, Christian Trépo14, Jia-Horng Kao15, Fabrice Carrat16, Karine Lacombe16, Raymond F Schinazi17, Françoise Barré-Sinoussi18, Jean-François Delfraissy19, Fabien Zoulim14.   

Abstract

HBV infection is a major cause of liver cirrhosis and hepatocellular carcinoma. Although HBV infection can be efficiently prevented by vaccination, and treatments are available, to date there is no reliable cure for the >240 million individuals that are chronically infected worldwide. Current treatments can only achieve viral suppression, and lifelong therapy is needed in the majority of infected persons. In the framework of the French National Agency for Research on AIDS and Viral Hepatitis 'HBV Cure' programme, a scientific workshop was held in Paris in June 2014 to define the state-of-the-art and unanswered questions regarding HBV pathobiology, and to develop a concerted strategy towards an HBV cure. This review summarises our current understanding of HBV host-interactions leading to viral persistence, as well as the roadblocks to be overcome to ultimately address unmet medical needs in the treatment of chronic HBV infection. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.

Entities:  

Keywords:  HEPATITIS B

Mesh:

Substances:

Year:  2015        PMID: 25670809     DOI: 10.1136/gutjnl-2014-308943

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  93 in total

1.  Non-nucleoside hepatitis B virus polymerase inhibitors identified by an in vitro polymerase elongation assay.

Authors:  Shogo Nakajima; Koichi Watashi; Kento Fukano; Senko Tsukuda; Kousho Wakae; Hideki Aizaki; Masamichi Muramatsu; Takaji Wakita; Tetsuya Toyoda
Journal:  J Gastroenterol       Date:  2019-11-25       Impact factor: 7.527

2.  Hepatitis B virus molecular biology and pathogenesis.

Authors:  R Jason Lamontagne; Sumedha Bagga; Michael J Bouchard
Journal:  Hepatoma Res       Date:  2016-07-01

Review 3.  Global strategies are required to cure and eliminate HBV infection.

Authors:  Peter Revill; Barbara Testoni; Stephen Locarnini; Fabien Zoulim
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-02-24       Impact factor: 46.802

4.  New perspectives on the hepatitis B virus life cycle in the human liver.

Authors:  Peter A Revill; Stephen A Locarnini
Journal:  J Clin Invest       Date:  2016-02-22       Impact factor: 14.808

Review 5.  Immune therapy for hepatitis B.

Authors:  Sheikh Mohammad Fazle Akbar; Mamun Al-Mahtab; Md Sakilur Islam Khan; Ruksana Raihan; Ananta Shrestha
Journal:  Ann Transl Med       Date:  2016-09

6.  Robust Human and Murine Hepatocyte Culture Models of Hepatitis B Virus Infection and Replication.

Authors:  Luhua Qiao; Jianhua Sui; Guangxiang Luo
Journal:  J Virol       Date:  2018-11-12       Impact factor: 5.103

Review 7.  Approved Antiviral Drugs over the Past 50 Years.

Authors:  Erik De Clercq; Guangdi Li
Journal:  Clin Microbiol Rev       Date:  2016-07       Impact factor: 26.132

Review 8.  Toward Elimination of Hepatitis B Virus Using Novel Drugs, Approaches, and Combined Modalities.

Authors:  Sebastien Boucle; Leda Bassit; Maryam Ehteshami; Raymond F Schinazi
Journal:  Clin Liver Dis       Date:  2016-08-30       Impact factor: 6.126

9.  New horizon for radical cure of chronic hepatitis B virus infection.

Authors:  Kazuto Tajiri; Yukihiro Shimizu
Journal:  World J Hepatol       Date:  2016-07-28

Review 10.  The evolution and clinical impact of hepatitis B virus genome diversity.

Authors:  Peter A Revill; Thomas Tu; Hans J Netter; Lilly K W Yuen; Stephen A Locarnini; Margaret Littlejohn
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-05-28       Impact factor: 46.802

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.